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Stockerau, Stockerau, Austria; 2Expert Witness for Statistics 
Certified by Court, Vienna, Austria 
Aim of Study: Diacerein is a symptomatic slow acting drug in 
osteoarthritis (SYSADOA) and there is substantial evidence in 
the literature about its efficacy and tolerability. The main objective 
of this Austrian postmarketing surveillance project was to pro- 
vide quantitative data about diacerein performance under prac- 
tical conditions in patients suffering from osteoarthritis (OA). 
Methods: The study design was a prospective, open, longitudi- 
nal patient collective observation over a period of 6 months with 
monthly visits. Efficacy variables were joint pain at rest and on 
movement measured on a 100-mm visual analogue scale (VAS) 
and global assessment of quality of life by the patient and physi- 
cian (Likert scale). Safety was assessed by types and frequen- 
cies of adverse events. An exploratory evaluation strategy based 
on the intention to treat principle was performed. Intraindividual 
comparisons were based on the non-parametric sign test using 
the two-sided 5% level of statistical significance. 
Results: 310 patients, diagnosed with OA of different joints, were 
recruited into this study (average age 62 years, 60% women). The 
study was conducted from July 2004 to July 2005 in the practices 
of 56 Austrian physicians. There were 76% of patients pretreated 
and the median pretreatment duration was 1.3 years. A total of 
67% of the patients had OA of the knee, 29% of the hip, 25% of 
the fingers and 39% of other joints. It was possible to collect data 
over the 6-month treatment period for 60% of the patients. 
VAS pain at rest and on movement and quality of life assessments 
by the patient and physician showed statistically significant im- 
provements (p<0.001) as compared to baseline from Month 1 on- 
wards. Gastrointestinal disorders were the main adverse events 
reported; they were generally mild to moderate and of transient 
nature, and only occasionally led to premature diacerein discon- 
tinuation. 
Conclusion: It is acknowledged that clinical studies have a high 
degree of internal validity but also widely lack patient population 
representativity. Therefore, data from clinical practice are essen- 
tial for making informed therapeutic decisions. 
Complete data could be gathered for only 60% of the patients. 
This may be related to the fact that the product is not reim- 
bursed by the Austrian social security system. Therefore, patients 
and physicians had to either make substantial efforts to achieve 
exceptional social security coverage, have an additional private 
health insurance or pay by themselves. 
The results of this study indicate a significant symptomatic effi- 
cacy and a good tolerability of diacerein. This suggests that diac- 
erein has a positive benefit/risk ratio in a clinical setting. In sum- 
mary, the results are in line with the currently published data on 
diacerein. 
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Rationale: Non Animal Stabilized Hyaluronic Acid (NASHA) has 
been suggested to be effective for treating symptoms of patients 
suffering from hip osteoarthritis (OA) 
Aim: To determine the predictive factors of long term efficacy 
of viscosupplementation by NASHA in patients with symptomatic 
hip OA. 
Methods: Open prospective trial. Patients: Thirty patients suf- 
fering from hip OA. Methods: Intra articular injection of NASHA 
(3ml) in the hip under fluoroscopy. Follow-up visits at day 7-30-60- 
90-180. Evaluation: Walking pain on 100 mm VAS, WOMAC in- 
dex, patient's global assessment; Lequesne index; Non steroidal 
anti inflammatory drugs (NSAIDs) and analgesics consumption. 
Efficacy was assessed by comparing the mean variation of the 
outcome variables to that defining the Minimal Clinically Impor- 
tant Improvement (MCII), and by comparing the end-point val- 
ues to that determining the Patient Acceptable Symptom State 
(PASS +). Statistics: Intent-to-treat nalysis. Predictive factors for 
response were studied using logistic regression analysis. 
Results: The mean decrease of all the outcome variables was 
higher than MCII. Patients who were responsive to treatment 
(PASS+) were characterized at baseline by a lower level of pain 
and disability (pain, patient's assessment, WOMAC Lequesne in- 
dex respectively 45.6, 44.6, 30 and 8.2) than PASS - patients 
(60.7, 62.3, 50 and 10), and by a shorter disease duration (30 vs 
79 months). The result at D30 was highly predictive of the result 
at D180 (P<0.002). 
Conclusion: The present data suggest that a single intra- 
articular injection of NASHA is effective to relieve durably pain 
in patients suffering from hip OA, particularly in those with mod- 
erate condition. 
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Aim: The role of arthroscopy in osteoarthritis (OA) of the knee 
remains to be defined and few clinical and radiographic harac- 
teristics have been quantitatively associated with outcome. The 
hypothesis of this study is that outcome after arthroscopic de- 
bridement for OA of the knee is associated with preoperative clin- 
ical and radiographic features and intraoperative characteristics 
and that subsets of patients exist that are more and less likely to 
respond favorably. 
Abstract P173 - Table 1 
Outcome measures Baseline End-point variation p PASS MCII 
median (mm) median (mm) mm (%) mm mm (%) 
Walking pain 53.6 34 -19.6(-36.6) 0.04 35.0 -15.3(-32) 
Patient's assessment 51.1 27.5 -23.6(-46.2) 0.004 34.6 - 15.2(-32.6) 
WOMAC 40.0 30.4 -9.6(-23.5) ns 34.4 -7.9(-21 )
Lequesne index 9.1 6.1 -3(-33.3) 0.05 na na 
